Remdesivir company CEO: It’s ‘not a cure, but a very significant treatment’


In the wake of a government-sponsored clinical trial that showed promising results for the experimental drug remdesivir to treat coronavirus, Daniel O’Day, chairman and CEO of Gilead Sciences, talks to TODAY in an NBC News exclusive. He says it’s “not a cure, but a very significant treatment” that can “reduce the time it takes patients to get better,” reducing the strain on health care systems. He promises Gilead will work to make the drug “accessible and affordable,” and says they are looking at ways to use the drug for other patients besides the most severely ill.